Vildagliptin and biguanide on postprandial blood glucose and vascular endothelial function in type 2 diabetic patients with coronary artery disease

UMIN ID: UMIN000010624

Registered date:01/05/2013

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Type 2 diabetic patients with coronary artery disease
• Date of first enrollment: 2013/04/01
• Target sample size: 20
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Vildagliptin
Metformin

Outcome(s)

• Primary Outcome: Changes of blood glucose, insulin, and lipids
• Secondary Outcome: Changes of vascular endothelial function

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1) Patients who has a history of adverse events with vildagliptin or biganide 2) Patients treated with antidiabetes agents 3) Ongoing treatment with insulin 4) Patients with diabetic ketoacidosis or diabetic coma or type 1 diabetes 5) Patients with severe liver dysfunction 6) Patients with moderate or severe renal disorders (creatinine level >= 1.5 mg/dL [men] or >= 1.3 mg/dL [women]) 7) Pregnant or nursing women 8) Patients with severe illness 9) Patients who judged as ineligible by clinical investigators

Related Information

• Primary Sponsor: Department of Cardiology, Juntendo University School of Medicine
• Source(s) of Monetary Support: None